Gentamicin nephrotoxicity: failure of three cephalosporins to potentiate injury in rats.

Antimicrobial Agents and Chemotherapy
W O HarrisonM Turck

Abstract

The possibility that gentamicin and cephalosporin antibiotics may act synergistically to produce nephrotoxicity was evaluated in an experimental model. Necrosis of the proximal tubules occurred when rats were treated with 60 to 120 mg/kg of gentamicin for 5 days but not when 15 to 20 mg/kg per day was given for up to 4 weeks. In all gentamicin-treated animals lysosomes of proximal tubules were increased in size and number and the lumens of many tubules contained a granular deposit. Examination by electron microscopy revealed that the abnormal lysosomes contained membranous whorls. The luminal deposits consisted of similar material; identical bodies were also present in the urinary sediment. To determine whether concurrent administration of a cephalosporin would augment the nephrotoxic potential of gentamicin, additional rats were treated for 4 weeks with daily injections of gentamicin (20 mg/kg) and either cephaloridine, cephalothin, or cefazolin (500 mg/kg). None of the combination regimens produced any more injury than did gentamicin alone.

References

Jul 1, 1970·The Journal of Infectious Diseases·F SilverblattR Bulger
Apr 1, 1969·The Journal of Infectious Diseases·F G FalcoG M Arcieri
Mar 1, 1974·Kidney International·F J Silverblatt
Dec 1, 1972·The Journal of Infectious Diseases·D H LawsonA L Linton
Dec 18, 1972·JAMA : the Journal of the American Medical Association·S N BobrowR C Young
May 19, 1973·British Medical Journal·J P FillastreM Robert
Apr 1, 1973·British Journal of Anaesthesia·G A BarrJ C Kosek
Apr 1, 1973·British Journal of Anaesthesia·R I Mazze, M J Cousins
Oct 1, 1973·The Journal of Infectious Diseases·F SilverblattM Turck
Jan 1, 1966·Annual Review of Physiology·C De Duve, R Wattiaux

❮ Previous
Next ❯

Citations

Jul 30, 1978·European Journal of Clinical Pharmacology·A W MondorfW Schoeppe
Oct 1, 1994·General Pharmacology·F V IzzettinS J Stohs
Oct 1, 1978·Disease-a-month : DM·J J Rahal, M S Simberkoff
Mar 24, 1977·The New England Journal of Medicine·G B Appel, H C Neu
Oct 1, 1977·Antimicrobial Agents and Chemotherapy·J S WoldN V Owen
Mar 1, 1978·Antimicrobial Agents and Chemotherapy·G L HagstromD R Maxwell
Jan 1, 1979·Antimicrobial Agents and Chemotherapy·R BlochD R Maxwell
Apr 1, 1976·Antimicrobial Agents and Chemotherapy·P DellingerL Weinstein
May 1, 1976·Antimicrobial Agents and Chemotherapy·F C LuftS A Kleit
Jul 1, 1982·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·H D HumesT C Knauss
Feb 1, 1992·Prostaglandins, Leukotrienes, and Essential Fatty Acids·N PapanikolaouJ Bariety
Mar 1, 1988·Journal of Veterinary Pharmacology and Therapeutics·K A Caprile
Jul 1, 1988·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·J CampsJ Rodés
Nov 1, 1980·The American Journal of Medicine·W M BennettG A Porter
Nov 1, 1995·Clinical Nephrology·T AkibaF Marumo
Apr 1, 1981·Drug Intelligence & Clinical Pharmacy·J C MannionN G Popovich
Oct 25, 1977·Naunyn-Schmiedeberg's Archives of Pharmacology·M Just, E Habermann
Jan 1, 1976·Antimicrobial Agents and Chemotherapy·P DellingerL Weinstein
Nov 1, 1980·Kidney International·G J Kaloyanides, E Pastoriza-Munoz

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.